Abstract: A method for inhibiting a flash point of trans-1,2-dichloroethylene (T-1,2-DCE) and a use of T-1,2-DCE are provided. The T-1,2-DCE has an excellent cleaning effect and is environmental friendly but cannot be used alone because of huge safety hazard caused by its low flash point. 1-chloro-3,3,3-trifluoropropene (HCFO-1233zd) is used to inhibit the flash point of T-1,2-DCE. However, because the actual boiling points of these two substances are quite different, the two substances are easily separated at a slightly-high ambient temperature. Because a boiling point of HCFO-1233zd is extremely low, HCFO-1233zd will escape rapidly, resulting in the loss of inhibition on the flash point. In the present disclosure, T-1,2-DCE and 1-chloro-2,3,3-trifluoropropene are mixed to prepare a mixed solution, and the mixed solution can effectively maintain the inhibition on the flash point of T-1,2-DCE in various ambient temperatures, such that the T-1,2-DCE can be heated to generate a steam for cleaning.

Abstract: An antioxidant for use in treatment for a radiation-induced bystander effect to a transplanted cell in a host is provided. The antioxidant is N-acetyl-L-cysteine, sulforaphane or resveratrol, or a combination thereof. The RIBE on transplanted human hematopoietic cells impaired the long-term hematopoietic reconstitution of human HSCs as well as the colony-forming ability of HPCs, and the RIBE-affected human hematopoietic cells showed enhanced DNA damage responses, cell cycle arrest and p53-dependent apoptosis, mainly due to oxidative stress. Taken together, these findings suggest that RIBE impairs human HSCs by oxidative DNA damage. The present disclosure provides definitive evidence for RIBE in transplanted human HSCs and further justifies the necessity for conducting clinical trials to assess the ability of multiple antioxidants to improve the efficacy of HSC transplantation for patients with hematological or non-hematological disorders.

Abstract: A preparation method of 1-chloro-2,3,3-trifluoropropene is provided. As a new eco-friendly compound that makes up a heat transfer medium, the 1-chloro-2,3,3-trifluoropropene (HCFO-1233yd) has been valued in the field of industrial cleaning and explosion-proof due to it excellent performance of low global warming potential (GWP) and ozone depletion potential (ODP) values, but HCFO-1233yd has high preparation cost that limits its large-scale application. In the preparation method of the present disclosure, 1,1,2,3,3-pentachloropropane is fluorinated into 1,2-dichloro-3,3-difluoropropene under the catalysis of a chromium-containing solid catalyst.

Abstract: A method for inhibiting a flash point of trans-1,2-dichloroethylene (T-1,2-DCE) and a use of T-1,2-DCE are provided. The T-1,2-DCE has an excellent cleaning effect and is environmental friendly but cannot be used alone because of huge safety hazard caused by its low flash point. 1-chloro-3,3,3-trifluoropropene (HCFO-1233zd) is used to inhibit the flash point of T-1,2-DCE. However, because the actual boiling points of these two substances are quite different, the two substances are easily separated at a slightly-high ambient temperature. Because a boiling point of HCFO-1233zd is extremely low, HCFO-1233zd will escape rapidly, resulting in the loss of inhibition on the flash point. In the present disclosure, T-1,2-DCE and 1-chloro-2,3,3-trifluoropropene are mixed to prepare a mixed solution, and the mixed solution can effectively maintain the inhibition on the flash point of T-1,2-DCE in various ambient temperatures, such that the T-1,2-DCE can be heated to generate a steam for cleaning.

Abstract: The present invention provides a method for treating leukemia utilizing somatic cell reprogramming. The method includes a step of introduction of somatic cell reprogramming inducing factors Oct-4, Sox-2, Klf4 and c-Myc (OSKM for short) into leukemic cells or a step of utilizing small reprogramming molecules in in-vitro culture. It promotes leukemic cells to initiate process of somatic cell reprogramming in order to induce apoptosis and finally purpose of eliminating leukemic cells in-vivo or in-vitro is achieved. It provides new ideas and methods for clinical treatment of leukemia in the future.

Abstract: The present invention provides a method for treating leukemia utilizing somatic cell reprogramming. The method includes a step of introduction of somatic cell reprogramming inducing factors Oct-4, Sox-2, Klf4 and c-Myc (OSKM for short) into leukemic cells or a step of utilizing small reprogramming molecules in in-vitro culture. It promotes leukemic cells to initiate process of somatic cell reprogramming in order to induce apoptosis and finally purpose of eliminating leukemic cells in-vivo or in-vitro is achieved. It provides new ideas and methods for clinical treatment of leukemia in the future.